ORIGINAL ARTICLE

Rapid antimicrobial susceptibility testing of clinical isolates by digital time-lapse microscopy

M. Fredborg1,4 · F. S. Rosenvinge2 · E. Spillum3 · S. Kroghsbo3 · M. Wang4 · T. E. Sondergaard5

Abstract Rapid antimicrobial susceptibility testing (AST) is essential for early and appropriate therapy. Methods with short detection time enabling same-day treatment optimisation are highly favourable. In this study, we evaluated the potential of a digital time-lapse microscope system, the oCelloScope system, to perform rapid AST. The oCelloScope system demonstrated a very high accuracy (96 % overall agreement) when determining the resistance profiles of four reference strains, nine clinical isolates, including multi-drug-resistant isolates, and three positive blood cultures. AST of clinical isolates (168 antimicrobial agent–organism combinations) demonstrated 3.6 % minor, no major and 1.2 % very major errors of the oCelloScope system compared to conventional susceptibility testing, as well as a rapid and correct phenotypic detection of strains with methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum β-lactamase (ESBL) profiles. The net average time-to-result was 108 min, with 95 % of the results being available within 180 min. In conclusion, this study strongly indicates that the oCelloScope system holds considerable potential as an accurate and sensitive AST method with short time-to-result, enabling same-day targeted antimicrobial therapy, facilitating antibiotic stewardship and better patient management. A full-scale validation of the oCelloScope system including more isolates is necessary to assess the impact of using it for AST.

Introduction

Bacterial multidrug resistance is emerging worldwide at an alarming rate and is now recognised as a major public health threat [1]. This crisis is not likely to be solved by new antibiotics due to the low rate of antibiotic discovery and by the probability that pathogens will continue to evolve resistance to antibiotics. The initiation of effective antibiotic therapy early in the course of an infection may reduce the probability of pathogens evolving resistance [2]. Especially in the case of sepsis and bloodstream infections, early appropriate antimicrobial therapy is important to decrease mortality [3]. Sepsis management includes empirical antimicrobial therapy started as soon as possible without awaiting results from antimicrobial susceptibility testing (AST) [4, 5]. As empirical antimicrobial therapy is mainly composed of broad-spectrum antibiotics, this can perpetuate the cycle of increasing resistance [6]. Consequently, early determination of antimicrobial susceptibility is pivotal in targeted antimicrobial therapy in order to combat the escalating rates of resistance, as well as to decrease mortality.

Today, AST in routine clinical microbiology laboratories is generally performed by conventional methods such as disc diffusion, broth dilution or Etest [7, 8]. During the last decade, several technologies have been suggested as candidates for more accurate AST, e.g. whole-genome sequencing, mass spectrometry, fluorescence-activated cell sorting and microarrays [7]. Technologies relying on genotypic and proteomic
analysis of resistance determinants such as whole-genome sequencing, polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) have the key limitation in that they are unable to detect novel resistance mechanisms [9, 10]. In addition, some of these new techniques are time-consuming and characterised by expensive instruments, high analysis costs, the need for specialised technical personnel and are, in some cases, limited by single-sample analysis. Automated instruments such as Vitek 2 (bioMérieux), Phoenix 100 (BD Biosciences) and MicroScan WalkAway (Siemens) are commonly used methods for AST as they are easy to operate and reduce the time-to-result [11–14]. Nevertheless, in clinical practice, even faster AST methods are required if effective treatment with targeted antibiotic is to be achieved within the same working day.

In a previous study, we demonstrated the oCelloScope system to be a fast and sensitive, high-throughput AST method capable of detecting antibiotic microbiology within 6 min for *Escherichia coli* and within 30 min in complex urine samples from pigs suffering from urinary tract infections [15]. In this study, we performed a preliminary evaluation of the ability of the oCelloScope system to analyse antimicrobial resistance by monitoring bacterial cell growth. The accuracy of the oCelloScope system was examined together with the time required for AST. This initial screening constitutes the proof of concept of the oCelloScope system in relation to AST of clinical isolates.

### Materials and methods

#### Strains

Four quality control (QC) reference strains were included to validate the antimicrobial susceptibility results obtained by the oCelloScope system: *Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 29213, *Enterococcus faecalis* ATCC 29212 and *Streptococcus pneumoniae* ATCC 49619. The QC reference strains used are recommended for quality control by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). In addition, nine clinical isolates, collected in Denmark during the period 2008–2012, were included: two *S. epidermidis* [one oxacillin resistant (mecA-positive) and one oxacillin and penicillin susceptible], one *S. pneumoniae* (penicillin intermediate and trimethoprim/sulphamethoxazole resistant), two *S. aureus* [one methicillin-resistant *S. aureus* (MRSA) (mecA-positive) and one methicillin-susceptible *S. aureus* (MSSA)], two *E. faecalis* [both gentamicin high-level resistant and one vancomycin resistant (vanB-positive)] and two *E. coli* [one extended-spectrum β-lactamase (ESBL) and one resistant to ampicillin, gentamicin and ciprofloxacin].

### Blood culture instrumentation and media

Blood samples from patients (8–10 mL/patient) with suspected bacteraemia were collected in standard aerobe non-charcoal BacT/ALERT FA blood culture bottles (bioMérieux, Marcy-l’Etoile, France) and handled according to the manufacturer’s instructions. Blood culture bottles were incubated in the BacT/ALERT 3D system (bioMérieux, Marcy-l’Etoile, France) at Aarhus University Hospital (Aarhus, Denmark). Blood cultures detected as positive by the BacT/ALERT 3D system were Gram stained and examined for bacterial morphology by light microscopy. All blood cultures used in this study were recognised as positive during the night and not processed until 8 o’clock the following morning. Species identification of isolates by the clinical laboratory was provided after the completion of oCelloScope AST measurements. Consequently, only preliminary phenotypic characterisation including Gram staining and examination of cellular morphology by light microscopy was provided prior to oCelloScope AST.

### Antimicrobial susceptibility testing by manually interpreted Sensititre® plates

AST was performed on all bacterial isolates using the Sensititre® system (TREK Diagnostic Systems, Cleveland, OH, USA), according to the manufacturer’s instructions. Three different Sensititre® plates were used: NF; *E. coli*, GPALLIF: Staphylococci and Enterococci, and STP6F: *S. pneumoniae*. Bacterial isolates were grown overnight on 5 % horse blood agar (Statens Serum Institut, Copenhagen, Denmark). Colony material was emulsified in sterile water (*E. coli, Staphylococcus spp. and Enterococcus spp.*) or Sensititre® cation-adjusted Mueller–Hinton broth with TES (CAMHB, TREK Diagnostic Systems, *S. pneumoniae*) and the suspension was adjusted to 0.5 McFarland standard using the Vitek DensiChek densitometer (bioMérieux). For *Staphylococcus spp., Enterococcus spp. and E. coli*, 10 μL was transferred into 11 mL CAMHB and 50 μL of the suspension was inoculated into each well on the Sensititre® plate. For *S. pneumoniae*, 100 μL was transferred into 11 mL Sensititre® cation-adjusted Mueller–Hinton broth with TES and lysed horse blood (CAMHB+LHB, TREK Diagnostic Systems) and 100 μL of the suspension was inoculated into each well on the Sensititre® plate. Plates were incubated for 20–24 h at 35 °C. For each test, we performed an inoculum check according to the manufacturer’s instructions. AST results were read using the Sensititre® Manual viewer.

### Antimicrobial susceptibility testing by the oCelloScope system

QC reference strains and clinical isolates were grown under atmospheric conditions at 37 °C in CAMHB, except
**Data analysis**

Bacterial susceptibility data for the QC reference strains obtained by the oCelloScope system were compared to QC ranges reported by TREK Diagnostic Systems (version 2.0). The TREK QC ranges were identical to the ranges given by the CLSI (M100-S23, 2013), with penicillin against *S. aureus* ATCC 29213 being the only outlier (Table 1). For clinical and blood culture isolates, antimicrobial susceptibility data obtained by the oCelloScope system were compared to manually read Sensititre® plates. The results from manually read Sensititre® plates were regarded as the gold standard. The time-to-result was measured from when the oCelloScope initiated image recording; the bacterial inoculum had been in contact with antimicrobials for approximately 10 min at this time point.

Essential agreement was defined as MIC agreement within $\pm$ one log$_2$. All clinical isolates were classified as S (susceptible), I (intermediate) or R (resistant) according to the CLSI breakpoints (M100-S23, 2013). Categorical agreement was defined as agreement within the S-I-R classification. Minor errors were defined as susceptible or resistant isolates misclassified as intermediate or intermediate isolates classified as resistant or susceptible, major errors were defined as susceptible isolates classified as resistant and very major errors were defined as resistant isolates classified as susceptible.

GraphPad Prism version 6.00 for Windows (GraphPad Software, San Diego, CA, USA) was used for data and statistical analysis, as well as graphing.

---

**Fig. 1** Example of an oCelloScope image and graphical output. a Growth curves for *S. aureus* ATCC29213 treated with vancomycin (0.25–32 mg/L) and without as a positive control (POS CON). b 2D picture of *S. aureus* ATCC29213 obtained by the oCelloScope system, with a magnitude comparable to a 200× magnification in a standard light microscope.
Table 1  Correlation between the oCelloScope system and TREK QC ranges for antimicrobial susceptibility of QC reference strains

| Antimicrobial agent | E. coli ATCC25922 | S. pneumoniae ATCC 49619 | S. aureus ATCC 29213 | E. faecalis ATCC 29212 |
|---------------------|------------------|----------------------|---------------------|----------------------|
| Amikacin            | 2 (0.5–4)        | –                    | –                   | –                    |
| Ampicillin          | –                | –                    | –                   | 1 (0.5–1)            |
| Ampicillin/sulbactam 2:1 ratio | 4/2 (2/1–8/4) | –                    | –                   | –                    |
| Aztreonam           | ≤0.12 (0.06–0.25) | –                    | –                   | –                    |
| Ceftazidime         | 0.25 (0.06–0.5)  | –                    | –                   | –                    |
| Cefoperazone        | ≤0.25 (0.12–0.5)  | –                    | –                   | –                    |
| Cefoxitin screen    | –                | –                    | ≤6 (≤6)             | –                    |
| Cefotaxime          | ≤0.25 (0.03–0.12) | ≤0.25 (0.03–0.12)    | –                   | –                    |
| Ceftazidime         | 0.25 (0.06–0.5)  | –                    | –                   | –                    |
| Chloramphenicol     | 4 (2–8)          | 1 (2–8)              | 8 (2–16)            | 4 (4–16)             |
| Ciprofloxacin       | ≤0.06 (0.004–0.015) | –                | ≤0.25 (0.12–0.5)    | 0.5 (0.25–2)         |
| Clindamycin         | –                | 0.25 (0.03–0.12)     | ≤0.12 (0.06–0.25)   | >2 (4–16)            |
| Daptomycin          | –                | 0.06 (0.06–0.5)      | 0.5 (0.12–1)        | 2 (1–4)              |
| Erythromycin        | –                | ≤0.12 (0.03–0.12)    | 0.25 (0.25–1)       | 1 (1–4)              |
| Gentamicin          | 1 (0.25–1)       | –                    | ≤0.5 (0.12–1)       | –                    |
| Imipenem            | 0.12 (0.06–0.25) | –                    | –                   | –                    |
| Levofloxacin        | 0.03 (0.008–0.06) | 0.5 (0.5–2)          | 0.25 (0.06–0.5)     | 1 (0.25–2)           |
| Linezolid           | –                | 0.25 (0.25–2)        | 2 (1–4)             | 2 (1–4)              |
| Moxifloxacin        | –                | ≤0.5 (0.06–0.25)     | ≤0.06 (0.015–0.12)  | 0.12 (0.06–0.5)      |
| Nitrofurantoin      | –                | –                    | 16 (8–32)           | 16 (4–16)            |
| Oxacillin           | –                | –                    | 0.25 (0.12–0.5)     | >4 (8–32)            |
| Penicillin          | –                | 0.25 (0.25–1)        | 0.25* (0.12–1)      | 2 (1–4)              |
| Piperacillin         | 2 (1–4)          | –                    | –                   | –                    |
| Piperacillin/tazobactam 4 | 2/4 (1/4–4/4) | –                    | –                   | –                    |
| Quinupristin/dalfopristin | –                | –                    | 0.25 (0.25–1)       | 2 (2–8)              |
| Rifampin            | –                | –                    | ≤0.12 (0.004–0.015) | 0.5 (0.5–4)          |
| Tetracycline        | 2 (0.5–2)        | ≤0.5 (0.06–0.5)      | ≤0.5 (0.12–1)       | 16 (8–32)            |
| Ticarcillin         | 16 (4–16)        | –                    | –                   | –                    |
| Ticarcillin/clavulanic acid 2 | 8/2 (4/2–16/2) | –                    | –                   | –                    |
| Tigecycline         | –                | 0.06 (0.015–0.12)    | 0.06 (0.03–0.25)    | 0.12 (0.03–0.12)     |
| Tobramycin          | 1 (0.25–1)       | –                    | –                   | –                    |
| Trimethoprim/sulphamethoxazole | 0.12/2.38 (≤0.5/9.5) | ≤0.25/4.75 (0.12/2.4–1/19) | ≤0.12/2.38 (≤0.5/9.5) | ≤0.12/2.38 (≤0.5/9.5) |
| Vancomycin          | –                | ≤0.25 (0.12–0.5)     | 1 (1–4)             | 2 (1–4)              |

*: the antimicrobial is not present on the TREK Sensititre® plates chosen for AST. ≤: MIC value is below the range tested. >: MIC value is above the range tested. *: MIC value is different from those recommended in CLSI M100

Results

Antimicrobial susceptibility testing of quality control (QC) reference strains

The ability of the oCelloScope system to determine antibiotic susceptibility was assessed by testing four QC reference strains, E. coli ATCC25922, S. aureus ATCC29213, S. pneumoniae ATCC49619 and E. faecalis ATCC29212, using the Sensititre® microdilution plates. Figure 1 shows the image output (a) and growth curves (b) determined by the oCelloScope system for S. aureus ATCC29213. Agreements and discrepancies between MIC values obtained by the oCelloScope system and target QC ranges given by TREK Diagnostic Systems are presented in Table 1. Due to the concentration ranges of the antimicrobial panels, it was not possible to determine an exact MIC value for some antimicrobials (e.g. cefotaxime, tetracycline and trimethoprim/sulphamethoxazole). These values are given as ≤ the lowest concentration in the panel range (all wells without growth).
or than the highest concentration in the panel range (growth in all wells). A total of 72 bacteria–antibiotic combinations were analysed, resulting in 97% agreement between the results obtained by the oCelloScope system and the TREK target QC range. Similar results were obtained in three separate identical experiments. The average time-to-result for QC reference strains by the oCelloScope system was 102 min, with 93% of the results being available within 180 min (Table 2). Two discrepancies of the 72 bacteria–antibiotic combinations were observed: S. pneumoniae tested against chloramphenicol and clindamycin (Table 1). For chloramphenicol, the MIC value measured by the oCelloScope system was one log₂ concentration lower than the QC range, whereas the MIC value for clindamycin was one log₂ concentration higher than the QC range.

Antimicrobial susceptibility testing of clinical isolates

Nine clinical isolates representing five different bacterial species with distinctive resistance profiles were included in this study (see the section on the experimental procedures for further information). A total of 168 bacteria–antibiotic combinations were tested using the Sensititre® microdilution plates. MIC values obtained by the oCelloScope system were compared to MIC values obtained by manual reading of Sensititre® plates. The average time-to-result for bacterial isolates by the oCelloScope system was 100 min, with 95% of the results being available within 180 min (Table 2). The average essential and categorical agreement was 93% (156 of 168) and 93% (136 of 146), respectively. Bacteria–antibiotic combinations that were not in agreement with conventional methods are listed in Table 3. Two major errors (1.2%) were observed: S. epidermidis tested against nitrofurantoin and E. coli tested against chloramphenicol. Five minor errors (3.6%) were observed: one for S. pneumoniae and four for E. faecalis, where two isolates were classified as rifampicin susceptible, one isolate was classified as linezolid intermediate, one isolate was classified as vancomycin intermediate and one isolate was classified as erythromycin intermediate. There were no major errors for any of the clinical isolates.

Table 2 Time-to-result in minutes required for the oCelloScope system to gain AST results for four QC (ATCC) strains, nine clinical isolates and three positive blood cultures (BC)

| Strain                      | av. time | 25th percentile | 75th percentile | min | max |
|-----------------------------|----------|-----------------|-----------------|-----|-----|
| S. aureus ATCC              | 118      | 53              | 143             | 30  | 360 |
| E. coli ATCC                | 93       | 49              | 120             | 30  | 180 |
| E. faecalis ATCC            | 112      | 68              | 143             | 45  | 270 |
| S. pneumoniae ATCC          | 84       | 60              | 90              | 30  | 165 |
| S. aureus MRSA              | 75       | 30              | 90              | 30  | 240 |
| S. aureus MSSA              | 86       | 45              | 120             | 45  | 180 |
| S. epidermidis Pen-R        | 103      | 60              | 120             | 30  | 240 |
| S. epidermidis Pen-S        | 92       | 60              | 120             | 30  | 180 |
| S. pneumoniae               | 91       | 60              | 90              | 45  | 180 |
| E. coli ESBL                | 113      | 60              | 155             | 45  | 300 |
| E. coli Amp-R               | 117      | 60              | 120             | 30  | 390 |
| E. faecalis VRE             | 130      | 60              | 120             | 30  | 600 |
| E. faecalis Gen-R           | 94       | 45              | 180             | 30  | 180 |
| S. aureus BC                | 248      | 230             | 230             | 230 | 450 |
| E. coli BC                  | 109      | 90              | 120             | 45  | 280 |
| E. faecalis BC              | 62       | 45              | 75              | 30  | 105 |

Results are expressed as average time (av. time), 25th percentile, 75th percentile, minimum time-to-result (min) and maximum time-to-result (max).

Antimicrobial susceptibility testing on positive blood cultures

To evaluate the ability of the oCelloScope system to perform AST, three positive blood cultures were included. The selection of appropriate antimicrobial Sensititre® panels and growth media was based on morphology and Gram staining. Species identification of the bacteria was performed at Aarhus University Hospital and the results were not available prior to AST by the oCelloScope system. Table 4 shows the AST results obtained by the oCelloScope system compared to susceptibility results obtained by testing the positive blood cultures with the manual Sensititre® system. The average time-to-result for susceptibility testing by the oCelloScope system ranged from 1 to 4.2 h, depending on the bacteria–antibiotic combination and whether the bacteria had reached stationary

| Strain                      | av. time | 25th percentile | 75th percentile | min | max |
|-----------------------------|----------|-----------------|-----------------|-----|-----|
| S. aureus ATCC              | 118      | 53              | 143             | 30  | 360 |
| E. coli ATCC                | 93       | 49              | 120             | 30  | 180 |
| E. faecalis ATCC            | 112      | 68              | 143             | 45  | 270 |
| S. pneumoniae ATCC          | 84       | 60              | 90              | 30  | 165 |
| S. aureus MRSA              | 75       | 30              | 90              | 30  | 240 |
| S. aureus MSSA              | 86       | 45              | 120             | 45  | 180 |
| S. epidermidis Pen-R        | 103      | 60              | 120             | 30  | 240 |
| S. epidermidis Pen-S        | 92       | 60              | 120             | 30  | 180 |
| S. pneumoniae               | 91       | 60              | 90              | 45  | 180 |
| E. coli ESBL                | 113      | 60              | 155             | 45  | 300 |
| E. coli Amp-R               | 117      | 60              | 120             | 30  | 390 |
| E. faecalis VRE             | 130      | 60              | 120             | 30  | 600 |
| E. faecalis Gen-R           | 94       | 45              | 180             | 30  | 180 |
| S. aureus BC                | 248      | 230             | 230             | 230 | 450 |
| E. coli BC                  | 109      | 90              | 120             | 45  | 280 |
| E. faecalis BC              | 62       | 45              | 75              | 30  | 105 |

Results are expressed as average time (av. time), 25th percentile, 75th percentile, minimum time-to-result (min) and maximum time-to-result (max).
Table 3  AST of nine clinical isolates by the oCelloScope system and compared to the manually read Sensititre® system (gold standard)

| Organism      | No. of antimicrobials tested (antimicrobials with CLSI breakpoint) | Essential agreement ±1 log₂ (%) | Categorical agreement (S-I-R according to CLSI breakpoints) |
|---------------|--------------------------------------------------------------------|---------------------------------|----------------------------------------------------------|
| S. epidermidis| 19 (17)                                                             | 90                              | 97 % Minor errors 0 Major errors 1✅                    |
| S. pneumoniae | 20 (18)                                                             | 85                              | 94 % 1b Minor errors 0 Major errors 0                  |
| S. aureus     | 19 (17)                                                             | 100                             | 100 % Minor errors 0 Major errors 0                    |
| E. faecalis   | 15 (11)                                                             | 83                              | 78 % 5e Minor errors 0 Major errors 0                  |
| E. coli       | 22 (19)                                                             | 100                             | 98 % Minor errors 0 Major errors 1d                    |

Results are expressed as essential agreements ±1 log₂ and categorial agreements according to CLSI breakpoints

a S. epidermidis: one isolate classified as nitrofurantoin susceptible

b S. pneumoniae: one isolate classified as penicillin susceptible

c E. faecalis: two isolates classified as rifampicin susceptible, one isolate classified as linezolid intermediate, one isolate classified as vancomycin intermediate and one isolate classified as erythromycin intermediate

d E. coli: one isolate classified as chloramphenicol susceptible

growth phase prior to testing (Table 2). The overall essential agreement was 95 % (57 of 60). Two of the discrepancies were S. aureus tested against ampicillin (oCelloScope MIC=1 mg/L vs. Sensititre® MIC=4 mg/L) and S. aureus tested against penicillin (oCelloScope MIC=0.5 mg/L vs. Sensititre® MIC=4 mg/L). Both methods categorised the S. aureus isolate as resistant to penicillin. The third discrepancy was observed for E. coli tested against chloramphenicol (oCelloScope MIC 8 mg/L vs. Sensititre® MIC>16 mg/L). The categorical agreement was 100 % for S. aureus and E. faecalis.

Discussion

In this study, we performed an initial screening to evaluate the potential of the oCelloScope system to perform rapid AST. This initial screening constitutes proof-of-concept in relation to bloodstream infections and, although this is not a full validation of the oCelloScope system, the results are compared to commercially available systems.

Four QC reference strains were used to evaluate the ability of the oCelloScope system for susceptibility determination, as directed by standards for the assessment of antimicrobial susceptibility [16, 17], with 95 % of the results lying within the QC target range. Subsequently, the evaluation was extended to include 168 bacteria-antibiotic combinations of common blood culture pathogens with different resistance profiles, resulting in an overall agreement of 96 %. It has been reported that an overall error rate of <10 % should be obtainable for an accepted performance of susceptibility testing [18–20]. According to guidelines, categorical agreements should be >90 %, major errors should be <3 % and very major errors should be <1.5 % [21]. In this study, the AST results of bacteria-antibiotic combinations with CLSI defined breakpoints showed categorical agreement for 93 %, 1.2 % very major errors and no major errors when determined by the oCelloScope system.

The AST results obtained in the two multidrug-resistant organisms, an MRSA and an ESBL-producing E. coli, showed no discrepancies in categorical agreement. Evaluation of the Vitek 2 and Phoenix systems for AST on blood cultures demonstrated categorical agreement rates of 94.6 % for Vitek 2 and 100 % for Phoenix when analysing 20 methicillin-resistant staphylococci tested against five antimicrobial agents [13]. Categorical agreements for 23 ESBL-positive E. coli tested against three antimicrobial agents were 97.5 % and 98.1 % for Vitek 2 and Phoenix, respectively [13]. For the VRE strain, oCelloScope determined it as intermediate, while manual reading classified it as resistant to vancomycin. The VRE strain carried the vanB gene. The vanB genotype usually has a vancomycin MIC distribution in the range 8–32 mg/L and generally confers lower MIC to vancomycin than the vanA genotype (typical vancomycin MIC> 64 mg/L) [22]. Rapid detection of the vanB genotype has proven to be difficult in automated systems and has led to the development of optimised panels [23, 24]. The disc diffusion test, agar screen and Etest showed 93 %, 100 % and 100 % sensitivity for detecting the vanB genotype, respectively, although agar diffusion tests can be challenging, as they require careful assessment of zone edges (eucast.org, CLSI M100 [23]. Thus, a full validation of the oCelloScope system should include a panel of multidrug-resistant species to determine its potential to rapidly determine the resistance profiles of such strains.

VME were observed with nitrofurantoin for S. epidermidis and with chloramphenicol for E. coli, both categorised as susceptible by the oCelloScope system. In a previous study evaluating Vitek 2, essential agreements with nitrofurantoin were 93.7 % for staphylococci and 88.9 % for enterococci [25], indicating that susceptibility testing for nitrofurantoin may
be difficult for automated instruments. A minor error was observed for *E. faecalis* when tested against linezolid. Manual reading classified the isolate as susceptible (MIC values ≤1 mg/L and 2 mg/L), while the oCelloScope system classified both isolates as intermediate (MIC=4 mg/L for both isolates). This discrepancy may be explained by the fact that linezolid MIC is determined at 80–90 % inhibition of growth (i.e. visible growth in negative wells) for manual reading, while the oCelloScope system measured MIC at 100 % inhibition of growth. The oCelloScope software, however, can be adjusted to allow for 10–20 % growth. For all other discrepancies, measurements performed by the oCelloScope system resulted in lower MIC values than the manually read Sensititre® plates, which were expected, since rapid AST methods generally result in lower MIC values.

Based on the promising results from analysis of the clinical isolates, the ability of the oCelloScope system to analyse positive blood cultures was examined. Only one discrepancy was observed in the 60 bacteria–antibiotic combinations: *E. coli* against chloramphenicol. Two possible sources of errors in

| Table 4 Results of AST of positive blood cultures. Positive blood cultures analysed with the oCelloScope system compared to MIC values obtained by testing the blood culture isolates with the manually read Sensititre® system |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| **Antimicrobial agent**         | **oCelloScope MIC value (Sensititre® MIC value)** | **E. coli** | **S. aureus** | **E. faecalis** |
| Amikacin                        | ≤4 (≤4)                                  | –                        | –                        | –                        |
| Ampicillin                      | –                                        | 1 (4)                    | 1 (1)                    | –                        |
| Amoxicillin/sulbactam 2:1 ratio | ≤2/1 (≤2/1)                              | –                        | –                        | –                        |
| Aztreonam                       | ≤2 (≤2)                                  | –                        | –                        | –                        |
| Carbenicillin                   | ≤32 (≤32)                                | –                        | –                        | –                        |
| Ceftazidime                     | ≤1 (≤1)                                  | –                        | –                        | –                        |
| Cefepime                        | ≤2 (≤2)                                  | –                        | –                        | –                        |
| Cefoperazone                    | ≤4 (≤4)                                  | –                        | –                        | –                        |
| Cefotaxime                      | ≤4 (≤4)                                  | –                        | –                        | –                        |
| Ceftriazone                     | ≤4 (≤4)                                  | –                        | –                        | –                        |
| Chloramphenicol                 | 16 (8)                                   | 4 (8)                    | 8 (8)                    | –                        |
| Ciprofloxacin                   | ≤0.25 (≤0.25)                            | ≤1 (≤1)                  | ≤1 (≤1)                  | –                        |
| Clindamycin                     | –                                        | ≤0.5 (≤0.5)              | >2 (>2)                  | –                        |
| Daptomycin                      | –                                        | ≤0.5 (≤0.5)              | 1 (1)                    | –                        |
| Erythromycin                    | –                                        | ≤0.25 (0.5)              | 2 (2)                    | –                        |
| Gentamicin                      | ≤1 (≤1)                                  | ≤2 (≤2)                  | 16 (16)                  | –                        |
| Imipenem                        | ≤1 (≤1)                                  | –                        | –                        | –                        |
| Levofloxacin                    | ≤0.12 (≤0.12)                            | ≤0.25 (≤0.25)            | 1 (1)                    | –                        |
| Linezolid                       | –                                        | ≤1 (2)                   | 2 (2)                    | –                        |
| Lomefloxacin                    | ≤0.5 (≤0.5)                              | –                        | –                        | –                        |
| Moxifloxacin                    | –                                        | ≤0.25 (≤0.25)            | ≤0.25 (≤0.25)            | –                        |
| Nitrofurantoin                  | –                                        | ≤32 (≤32)                | ≤32 (≤32)                | –                        |
| Oxacillin                       | –                                        | ≤0.25 (≤0.25)            | >4 (>4)                  | –                        |
| Penicillin                      | –                                        | 0.5 (4)                  | 8 (4)                    | –                        |
| Piperacillin                    | ≤8 (≤8)                                  | –                        | –                        | –                        |
| Piperacillin/tazobactam 4       | ≤8/4 (≤8/4)                              | –                        | –                        | –                        |
| Quinupristin/dalfopristin       | –                                        | ≤0.5 (≤0.5)              | >4 (>4)                  | –                        |
| Rifampicin                      | –                                        | ≤0.5 (≤0.5)              | 2 (2)                    | –                        |
| Tetracycline                    | ≤1 (≤1)                                  | ≤2 (≤2)                  | >16 (>16)                | –                        |
| Ticarcillin                     | ≤8 (≤8)                                  | –                        | –                        | –                        |
| Ticarcillin/clavulanic acid 2   | ≤16/2 (≤16/2)                            | –                        | –                        | –                        |
| Tigecycline                     | –                                        | 0.12 (0.06)              | 0.25 (0.12)              | –                        |
| Tobramycin                      | ≤1 (≤1)                                  | –                        | –                        | –                        |
| Trimethoprim/sulphamethoxazole  | ≤0.5/9.5 (≤0.5/9.5)                      | ≤0.5/9.5 (≤0.5/9.5)      | ≤0.5/9.5 (≤0.5/9.5)      | –                        |
| Vancomycin                      | –                                        | 1 (1)                    | 2 (2)                    | –                        |

–: the antimicrobial was not included on the chosen TREK Sensititre® plate. ≤: MIC value is below the range tested. >: MIC value is above the range tested.
AST are direct inoculation of mixed cultures and non-standardised inoculum size [26–28]. In some cases, mixed blood cultures can be determined by microscopy and Gram staining and, thus, be excluded from the AST method. If the blood culture contains bacteria with different morphology, this would be visible in the oCelloScope system and precautions may be taken. In order to ensure standardised inoculum size, all bacterial cell suspensions were adjusted to McFarland 0.5. Although blood cells and traces of blood culture broth can interfere with measurements, this would be visible in the oCelloScope system when setting up the experiment. For many compounds, the MIC value increases as inoculum increases (e.g. *S. aureus* tested against ciprofloxacin, oxacillin and vancomycin), while other antimicrobials such as chloramphenicol or the tetracyclines are not associated with inoculum effects [29, 30]. An advantage of the oCelloScope system, as well as other growth-based susceptibility tests, is that it only takes live bacteria into account and that this method, in contrast to agar diffusion tests, is independent of the antibiotic diffusion rate and time to macroscopically visible growth. Taken together, the results from studies on QC reference strains, clinical isolates and positive blood cultures showed an overall high accuracy of the oCelloScope system.

A major aim of this study was to assess whether the oCelloScope system could reduce the turnaround time of AST compared to conventional AST methods. If so, the oCelloScope system might serve as an essential screening tool to accelerate appropriate antibiotic therapy. The benefits of timely reporting of susceptibility results have been highlighted previously [31, 32]. Testing of QC reference strains and clinical isolates resulted in an average time-to-result of 100 min, with MIC determination being possible for 43 % of the bacteria–antibiotic combinations within 1 h (Table 2). However, it is possible to decrease the time-to-result even further by optimising algorithms and software settings, as the oCelloScope system was set up to analyse every 15 min for 12 h. Naturally, if the oCelloScope system was set up to analyse every 5 min, the time-to-result would have been shorter. Furthermore, a 2-h culture step was included to ensure early to mid-exponential phase of growth of the bacteria prior to analysis by the oCelloScope system. In a clinical setting, this step could be omitted, as the technique of the oCelloScope system could be integrated into automated blood culturing systems and, therefore, perform AST directly on positive blood cultures.

For AST on the included positive blood cultures, the average time-to-result ranged from 1 to 4.5 h, depending on the bacteria–antibiotic combination and whether the bacteria had reached the stationary growth phase. All blood cultures used in this study became positive during the night and were not processed until 8 o’clock the following morning. Consequently, these cultures may have been positive for up to 13 h. A lag phase of 2 h was observed for the *S. aureus* blood culture, which is the major reason for the prolonged time-to-result compared to that of the QC reference strains and the clinical isolates. According to the manufacturer’s instructions, the incubation time of Sensititre® MIC plates should be 18 h. This means a reduction in the average time-to-result of approximately 16.5 h by using the oCelloScope system. The fastest commercially available automatic AST method (Vitek 2, bioMeriéux, France) requires approximately 8 h to detect antimicrobial resistances in bacteria [33]. Taken together, these results strongly indicate that the oCelloScope system has the potential to decrease the time-to-result for AST. Translating this into daily workflow entails that same-day treatment or adjustments of antibiotic therapy are possible with the oCelloScope system. Only a few methods enable AST under 1 h, and only one method enables the determination of a real MIC value; however, this method is currently not commercially available [7]. AST of blood cultures by oCelloScope using Sensititre® microdilution plates may be incorporated into the clinical laboratory workflow, with 95 % of the results being available within 3 h and can be confirmed by inspection of the movies provided for each of the 96 wells.

The results from the three different types of samples clearly show that several parameters influence the time-to-result, including bacterial growth phase, bacterial doubling time, mode-of-action of the antibiotic and bacterial expression of resistance genes. However, it is clear that the prolonged time-to-result for the positive blood cultures is due to the growth state of the bacteria. Large variations of the time-to-result were observed for all samples, depending on the antibiotic of concern. As the number of isolates and species tested are limited, these variations might evolve when a greater number are included. However, it is crucial to note that part of these variations may not be clinically relevant, due to, for example, the site of infection, expression of resistance genes or antibiotic preference.

To take full advantages of the oCelloScope technique in a clinical setting, it should be incorporated into a fully automatic system, such as the blood culture system, or further developed into a fully automatic AST system of its own, and, most importantly, be able to analyse the bacterial infection as early as possible. However, considering the current version of the oCelloScope system, analysing a 96-well plate of growth-optimised bacteria using autofocus, continuing image acquisition and automated data analysis, the total time-to-result of AST would be around 60–75 min for 90 % of the analysed antimicrobials. The flexibility of the software makes adaption possible to most laboratory information management systems, even with the integration of movies from each well to ensure confirmation and acceptance of the test results by clinicians. The time-to-result for bacterial identification has been shortened considerably by the use of mass spectrometry techniques, and, therefore, no longer represents the bottleneck of
AST. Consequently, the identification of a given infection is usually available before the results of AST and this information can, therefore, be incorporated into the data analysis part of the software.

Conclusion

Although our data are preliminary, this study suggests that the oCelloScope system can decrease detection time, making same-day reporting possible and, thus, permitting better patient management. With an overall agreement of 96 % for the nine tested isolates and three positive blood cultures, the rapid detection time does not interfere with sensitivity. Strains with methicillin-resistant *Staphylococcus aureus* (MRSA) and extended-spectrum β-lactamase (ESBL) resistance profiles were rapidly detected by the oCelloScope system. A full-scale validation of the oCelloScope system including more isolates is necessary to assess the impact of using it for antimicrobial susceptibility testing (AST).

Acknowledgements This work was supported by grants from the Danish National Innovation Foundation 137-2012 and from the Danish Agency for Science 10-100105. We thank Trine Poulsen for the excellent technical assistance.

Conflict of interest The authors declare competing financial interests. Declaration: M.F. is employed in a joint research project between Aarhus University, Aalborg University, the Danish National Innovation Foundation and Philips BioCell. E.S. and S.K. are employed at Philips BioCell.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Infectious Diseases Society of America (2011) Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52:S397–S428
2. Deresinski S (2007) Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 45:S177–S183
3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596
4. Cohen J (2009) Sepsis. Medicine 37:562–565
5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
6. Miczek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM et al (2010) Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 54:1742–1748
7. van Belkum A, Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J et al (2013) Rapid clinical bacteriology and its future impact. Ann Lab Med 33:14–27
8. Jenkins SG, Schuetz AN (2012) Current concepts in laboratory testing to guide antimicrobial therapy. Mayo Clin Proc 87:290–308
9. Pulido MR, Garcia-Quintanilla M, Martin-Peña R, Cisneros JM, McConnell MJ (2013) Progress on the development of rapid methods for antimicrobial susceptibility testing. J Antimicrob Chemother 68:2710–2717
10. Didelez X, Bowden R, Wilson DJ, Peto TE, Crook DW (2012) Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13:601–612
11. Chatzigogou K, Sergentanis TN, Tsiodras S, Hamodorakas SJ, Bagos PG (2011) Phoenix 100 versus Vitek 2 in the identification of gram-positive and gram-negative bacteria: a comprehensive meta-analysis. J Clin Microbiol 49:3284–3291
12. Duggal S, Gaind R, Tandon N, Deb M, Chugh TD (2012) Comparison of an automated system with conventional identification and antimicrobial susceptibility testing. ISRN Microbiol 2012: 107203. doi:10.5402/2012/107203
13. Gherardi G, Angeletti S, Panetti M, Pompilio A, Di Bonaventura G, Crea F et al (2012) Comparative evaluation of the Vitek-2 Compact and Phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of Gram-negative and Gram-positive isolates. Diagn Microbiol Infect Dis 72:20–31
14. Mittman SA, Huard RC, Della-Latta P, Whittier S (2009) Comparison of BD Phoenix to Vitek 2, MicroScan MICrOStREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol 47:3557–3561
15. Fredborg M, Andersen KR, Jorgensen E, Droece A, Olesen T, Jensen BB et al (2013) Real-time optical antimicrobial susceptibility testing. J Clin Microbiol 51:2047–2053
16. Wiegand I, Hilpert K, Hancock RE (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3:163–175
17. Schwarz S, Silley P, Simjee S, Woodford N, van Duijkeren E, Johnson AP et al (2010) Editorial: assessing the antimicrobial susceptibility of bacteria obtained from animals. J Antimicrob Chemother 65:601–604
18. Ferraro MJ, Jorgensen JH (1999) Susceptibility testing instrumentation and computerized expert systems for data analysis and interpretation. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 7th edn. American Society for Microbiology, Washington, DC, pp 1593–1600
19. Patel JB, Sharp S, Novak-Weekley S (2013) Verification of antimicrobial susceptibility testing methods: a practical approach. Clin Microbiol News 35:103–109
20. Richter SS, Ferraro MJ (2007) Susceptibility testing instrumentation and computerized expert systems for data analysis and interpretation. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (eds) Manual of clinical microbiology, 9th edn. ASM Press, Washington, DC, pp 245–256
21. Thombsberry C (1985) Automated procedures for antimicrobial susceptibility tests. In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ (eds) Manual of clinical microbiology, 4th edn. American Society for Microbiology, Washington, DC, pp 1015–1018
22. Rathe M, Kristensen I, Ellermann-Eriksen S, Thomsen MK, Schumacher H (2010) Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin. APMIS 118:66–73
23. Endtz HP, van den Braak N, van Belkum A, Kluytmans JA, Koeleman JG, Spanjaard L et al (1997) Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. J Clin Microbiol 35: 3026–3031

24. Winstanley T, Courvalin P (2011) Expert systems in clinical microbiology. Clin Microbiol Rev 24:515–556

25. Barry J, Brown A, Ensor V, Lakhani U, Petts D, Warren C et al (2003) Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J Antimicrob Chemother 51: 1191–1202

26. Trenholme GM, Kaplan RL, Karakusis PH, Stine T, Fuhrer J, Landau W et al (1989) Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates. J Clin Microbiol 27:1342–1345

27. Doern GV, Vautour R, Gaudet M, Levy B (1994) Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 32:1757–1762

28. Chapin K, Musgnug M (2003) Evaluation of three rapid methods for the direct identification of Staphylococcus aureus from positive blood cultures. J Clin Microbiol 41:4324–4327

29. Martinez M, Blondeau J, Cerniglia CE, Fink-Gremmels J, Guenther S, Hunter RP et al (2014) Workshop report: the 2012 antimicrobial agents in veterinary medicine: exploring the consequences of antimicrobial drug use: a 3-D approach. J Vet Pharmacol Ther 37:e1–e16

30. Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR (2009) Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother 63:745–757

31. Daniels R (2011) Surviving the first hours in sepsis: getting the basics right (an intensivist’s perspective). J Antimicrob Chemother 66:ii11–ii23

32. Gonsalves MD, Sakr Y (2010) Early identification of sepsis. Curr Infect Dis Rep 12:329–335

33. Eigner U, Schmid A, Wild U, Bertsch D, Fahr AM (2005) Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems. J Clin Microbiol 43:3829–3834